Matrix metalloproteinase activity and osteoclasts in experimental prostate cancer bone metastasis tissue

American Journal of Pathology

Volumn 166, Issue 4, 2005, Pages 1173-1186

  Dong, Zhong ^a   Bonfil, R Daniel ^a   Chinni, Sreenivasa ^a   Deng, Xiyun ^a   Trindade Filho, J Carlos ^a   Bernardo, Margarida ^a   Vaishampayan, Ulka ^a   Che, Mingxin ^a   Sloane, Bonnie F ^a   Sheng, Shijie ^a   Fridman, Rafael ^a   Cher, Michael L ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; MATRIX METALLOPROTEINASE INHIBITOR; RIBOZYME; SMALL INTERFERING RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE ATROPHY; BONE METASTASIS; CARCINOGENESIS; CELL INTERACTION; CELL MOTILITY; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVITY; FETUS; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MOUSE; NONHUMAN; OSTEOCLAST; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCID MOUSE; TUMOR CELL CULTURE; TUMOR VOLUME;

EID: 20244362234     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)62337-1     Document Type: Article

References (56)

1. Netto GJ, Humphrey PA: Molecular biologic aspects of human prostatic carcinoma. Am J Clin Pathol 1994, 102:S57-S64
2. Bubendorf L, Schopfer A, Wagner U, Sauter G, Moch H, Willi N, Gasser TC, Mihatsch MJ: Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol 2000, 31:578-583
3. Cheville JC, Tindall D, Boelter C, Jenkins R, Lohse CM, Pankratz VS, Sebo TJ, Davis B, Blute ML: Metastatic prostate carcinoma to bone: clinical and pathologic features associated with cancer-specific survival. Cancer 2002, 95:1028-1036
4. Carlin BI, Andriole GL: The natural history, skeletal complications, and management of bone metastases in patients with prostate carcinoma. Cancer 2000, 88:2989-2994
5. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ: Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001, 357:336-341
6. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev 2000, 14:163-176
7. John A, Tuszynski G: The role of matrix metalloproteinases in tumor angiogenesis and tumor metastasis. Pathol Oncol Res 2001, 7:14-23
8. Stearns ME, Wang M: Type IV collagenase (M(r) 72,000) expression in human prostate: benign and malignant tissue. Cancer Res 1993, 53:878-883
9. Festuccia C, Bologna M, Vicentini C, Tacconelli A, Miano R, Violini S, Mackay AR: Increased matrix metalloproteinase-9 secretion in short-term tissue cultures of prostatic tumor cells. Int J Cancer 1996, 69:386-393
10. Wood M, Fudge K, Mohler JL, Frost AR, Garcia F, Wang M, Stearns ME: In situ hybridization studies of metalloproteinases 2 and 9 and TIMP-1 and TIMP-2 expression in human prostate cancer. Clin Exp Metastasis 1997, 15:246-258
11. Upadhyay J, Shekarriz B, Nemeth JA, Dong Z, Cummings GD, Fridman R, Sakr W, Grignon DJ, Cher ML: Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia. Clin Cancer Res 1999, 5:4105-4110
12. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z: Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in expiant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. Cancer Res 1993, 53:4493-4498
13. Stearns M, Stearns ME: Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncol Res 1996, 8:69-75
14. Zhou Z, Apte SS, Soininen R, Cao R, Baaklini GY, Rauser RW, Wang J, Cao Y, Tryggvason K: Impaired endochondral ossification and angiogenesis in mice deficient in membrane-type matrix metalloproteinase I. Proc Natl Acad Sci USA 2000, 97:4052-4057
15. Holmbeck K, Bianco P, Chrysovergis K, Yamada S, Birkedal-Hansen H: MT1-MMP-dependent, apoptotic remodeling of unmineralized cartilage: a critical process in skeletal growth. J Cell Biol 2003, 163:661-671
16. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, Ward JM, Birkedal-Hansen H: MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 1999, 99:81-92
17. Colnot C, Thompson Z, Miclau T, Werb Z, Helms JA: Altered fracture repair in the absence of MMP9. Development 2003, 130:4123-4133
18. Engsig MT, Chen QJ, Vu TH, Pedersen AC, Therkidsen B, Lund LR, Henriksen K, Lenhard T, Foged NT, Werb Z, Delaisse JM: Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 2000, 151:879-889
19. Vu TH, Shipley JM, Bergers G, Berger JE, Helms JA, Hanahan D, Shapiro SD, Senior RM, Werb Z: MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell 1998, 93:411-422
20. Blavier L, Delaisse JM: Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 1995, 108:3649-3659
21. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R, Cher ML: Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis. J Natl Cancer Inst 2002, 94:17-25
22. Weber MH, Lee J, Orr FW: The effect of Neovastat (AE-941) on an experimental metastatic bone tumor model. Int J Oncol 2002, 20:299-303
23. Winding B, NicAmhlaoibh R, Misander H, Hoegh-Andersen P, Andersen TL, Holst-Hansen C, Heegaard AM, Foged NT, Brunner N, Delaisse JM: Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 2002, 8:1932-1939
24. Lee J, Weber M, Mejia S, Bone E, Watson P, Orr W: A matrix metalloproteinase inhibitor, batimastat, retards the development of osteolytic bone metastases by MDA-MB-231 human breast cancer cells in Balb C nu/nu mice. Eur J Cancer 2001, 37:106-113
25. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2002, 2:584-593
26. Kaighn ME, Narayan KS, Ohnuki Y, Lechner JF, Jones LW: Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest Urol 1979, 17:16-23
27. Kovacsovics-Bankowski M, Rock KL: A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 1995, 267:243-246
28. Brown PD: Matrix metalloproteinase inhibitors: a novel class of anti-cancer agents. Adv Enzyme Regul 1995, 35:293-301
29. Devy L, Hollender P, Munaut C, Colige A, Garnotel R, Foidart JM, Noel A, Jeannesson P: Matrix and serine protease expression during leukemic cell differentiation induced by aclacinomycin and all-transretinoic acid. Biochem Pharmacol 2002, 63:179-189
30. Sarin A, Adams DH, Henkart PA: Protease inhibitors selectively block T cell receptor-triggered programmed cell death in a murine T cell hybridoma and activated peripheral T cells. J Exp Med 1993, 178:1693-1700
31. Galardy RE, Grobelny D, Foellmer HG, Fernandez LA: Inhibition of angiogenesis by the matrix metalloprotease inhibitor N-[2R-2- (hydroxamidocarbonymethyl)-4-methylpentanoyl)]-L-tryptophan methylamide. Cancer Res 1994, 54:4715-4718
32. Wolf M, Clark-Lewis I, Buri C, Langen H, Lis M, Mazzucchelli L: Cathepsin D specifically cleaves the chemokines macrophage inflammatory protein-1 alpha, macrophage inflammatory protein-1 beta, and SLC that are expressed in human breast cancer. Am J Pathol 2003, 162:1183-1190
33. Nemeth JA, Harb JF, Barroso Jr U, He Z, Grignon DJ, Cher ML: Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 1999, 59:1987-1993
34. Dong Z, Nemeth JA, Cher ML, Palmer KC, Bright RC, Fridman R: Differential regulation of matrix metalloproteinase-9, tissue inhibitor of metailoproteinase-1 (TIMP-1) and TIMP-2 expression in co-cultures of prostate cancer and stromal cells. Int J Cancer 2001, 93:507-515
35. Sanceau J, Truchet S, Bauvois B: Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells. J Biol Chem 2003, 278:36537-36546
36. Okada Y, Gonoji Y, Naka K, Tomita K, Nakanishi I, Iwata K, Yamashita K, Hayakawa T: Matrix metalloproteinase 9 (92-kDa gelatinase/type IV collagenase) from HT 1080 human fibrosarcoma cells. Purification and activation of the precursor and enzymic properties. J Biol Chem 1992, 267:21712-21719
37. Knauper V, Smith B, Lopez-Otin C, Murphy G: Activation of progelatinase B (proMMP-9) by active collagenase-3 (MMP-13). Eur J Biochem 1997, 248:369-373
38. von Bredow DC, Cress AE, Howard EW, Bowden GT, Nagle RB: Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochem J 1998, 331:965-972
39. Zhao YG, Xiao AZ, Newcomer RG, Park HI, Kang T, Chung LW, Swanson MG, Zhau HE, Kurhanewicz J, Sang QX: Activation of pro-gelatinase B by endometase/matrilysin-2 promotes invasion of human prostate cancer cells. J Biol Chem 2003, 278:15056-15064
40. Fridman R, Toth M, Pena D, Mobashery S: Activation of progelatinase B (MMP-9) by gelatinase A (MMP-2). Cancer Res 1995, 55:2548-2555
41. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM, Meunier PJ: Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 1983, 51:918-924
42. Percival RC, Urwin GH, Harris S, Yates AJ, Williams JL, Beneton M, Kanis JA: Biochemical and histological evidence that carcinoma of the prostate is associated with increased bone resorption. Eur J Surg Oncol 1987, 13:41-49
43. Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD: Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000, 82:858-864
44. Yoneda T: Cellular and molecular mechanisms of breast and prostate cancer metastasis to bone. Eur J Cancer 1998, 34:240-245
45. Soos G, Haas GP, Wang CY, Jones RF: Differential gene expression in human prostate cancer cells adapted to growth in bone in Beige mice. Urol Oncol 2003, 21:15-19
46. Bastide C, Bagnis C, Mannoni P, Hassoun J, Bladou F: A Nod Seid mouse model to study human prostate cancer. Prostate Cancer Prostatic Dis 2002, 5:311-315
47. Chambers TJ, Fuller K: Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 1985, 76:155-165
48. Drake FH, Dodds RA, James IE, Connor JR, Debouck C, Richardson S, Lee-Rykaozewski E, Coleman L, Rieman D, Barthlow R, Hastings G, Gowen M: Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoolasts. J Biol Chem 1996, 271:12511-12516
49. Reponen P, Sahlberg C, Munaut C, Thesleff I, Tryggvason K: High expression of 92-kD type IV collagenase (gelatinase B) in the osteoclast lineage during mouse development. J Cell Biol 1994, 124:1091-1102
50. Tezuka K, Nemoto K, Tezuka Y, Sato T, Ikeda Y, Kobori M, Kawashima H, Eguchi H, Hakeda Y, Kumegawa M: Identification of matrix metalloproteinase 9 in rabbit osteoolasts. J Biol Chem 1994, 269:15006-15009
51. Everts V, Delaisse JM, Korper W, Beertsen W: Cysteine proteinases and matrix metalloproteinases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res 1998, 13:1420-1430
52. Yu X, Huang Y, Collin-Osdoby P, Osdoby P: Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 2003, 18:1404-1418
53. Lakka SS, Gondi CS, Yanamandra N, Olivero WC, Dinh DH, Gujrati M, Rao JS: Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 2004, 23:4681-4689
54. Matrisian LM, Sledge GW, Mohla S: Extracellular proteolysis and cancer: meeting summary and future directions. Cancer Res 2003, 63:6105-6109
55. Laxman B, Hall DE, Bhojani MS, Hamstra DA, Chenevert TL, Ross BD, Rehemtulla A: Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 2002, 99:16551-16555
56. Bremer C, Tung CH, Weissleder R: In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med 2001, 7:743-748